PAVmed (NASDAQ:PAVM) Stock Rating Lowered by Cantor Fitzgerald

Cantor Fitzgerald cut shares of PAVmed (NASDAQ:PAVMGet Rating) from an overweight rating to a neutral rating in a research report released on Friday, The Fly reports. Cantor Fitzgerald currently has $1.50 price objective on the stock, down from their previous price objective of $4.00.

PAVM has been the topic of several other research reports. Lake Street Capital reduced their price target on shares of PAVmed from $5.00 to $1.50 and set a buy rating on the stock in a research note on Wednesday, January 18th. Ascendiant Capital Markets set a $8.25 target price on shares of PAVmed in a research report on Thursday, November 24th.

PAVmed Stock Down 0.7 %

PAVM stock opened at $0.46 on Friday. PAVmed has a 52 week low of $0.40 and a 52 week high of $2.34. The firm has a market capitalization of $41.49 million, a P/E ratio of -0.47 and a beta of 0.79. The company has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $0.99.

PAVmed (NASDAQ:PAVMGet Rating) last announced its earnings results on Tuesday, November 15th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $0.08 million for the quarter. As a group, analysts anticipate that PAVmed will post -1.06 EPS for the current year.

Insider Buying and Selling at PAVmed

In other PAVmed news, Director Michael J. Glennon bought 62,000 shares of the business’s stock in a transaction on Monday, December 5th. The shares were acquired at an average price of $0.69 per share, with a total value of $42,780.00. Following the transaction, the director now owns 62,000 shares of the company’s stock, valued at approximately $42,780. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Michael J. Glennon bought 62,000 shares of the firm’s stock in a transaction that occurred on Monday, December 5th. The stock was bought at an average price of $0.69 per share, with a total value of $42,780.00. Following the completion of the transaction, the director now directly owns 62,000 shares of the company’s stock, valued at approximately $42,780. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael J. Glennon bought 100,000 shares of the stock in a transaction on Wednesday, December 7th. The stock was purchased at an average price of $0.62 per share, with a total value of $62,000.00. Following the completion of the purchase, the director now owns 250,000 shares of the company’s stock, valued at $155,000. The disclosure for this purchase can be found here. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On PAVmed

Institutional investors have recently bought and sold shares of the company. Pacific Wealth Management acquired a new stake in PAVmed in the second quarter valued at approximately $28,000. Private Advisor Group LLC boosted its stake in PAVmed by 40.8% in the first quarter. Private Advisor Group LLC now owns 31,823 shares of the company’s stock valued at $42,000 after acquiring an additional 9,215 shares in the last quarter. Guardian Wealth Advisors LLC acquired a new stake in shares of PAVmed during the third quarter worth $30,000. Glassman Wealth Services acquired a new stake in shares of PAVmed during the second quarter worth $33,000. Finally, UBS Group AG lifted its stake in shares of PAVmed by 777.9% during the third quarter. UBS Group AG now owns 41,200 shares of the company’s stock worth $35,000 after buying an additional 36,507 shares during the period. 13.98% of the stock is currently owned by institutional investors and hedge funds.

About PAVmed

(Get Rating)

PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes.

Further Reading

The Fly logo

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.